Join Us

Trodelvy

Save as Favorite
Sign in to receive recommendations (Learn more)

Brand name: Trodelvy

Chemical name: Sacituzumab govitecan-hziy

Class: Antibody-drug conjugate immune targeted therapy. Trodelvy is made up of:

  • sacituzumab, a type of protein called a monoclonal antibody, that targets the Trop-2 protein; the Trop-2 protein is found in more than 90% of triple-negative breast cancers
  • SN-38, a topoisomerase I inhibitor chemotherapy; topoisomerase I inhibitors work by interfering with the cancer cells’ ability to replicate
  • a compound that links the sacituzumab to the SN-38

The linking compound attaches (conjugates) the monoclonal antibody sacituzumab to the SN-38 chemotherapy.

Uses: Trodelvy is used to treat adults diagnosed with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more systemic therapies (such as chemotherapy or targeted therapy), at least one of which was for advanced-stage disease.

How it’s given: Trodelvy is given intravenously, which means the medicine is delivered directly into your bloodstream through an IV or port.

Side effects:

Read more about Trodelvy.

Join the Conversation


References

  1. Trodelvy (sacituzumab govitecan-hziy) prescribing information. Immunomedics, 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf (PDF)
  2. U.S. Food and Drug Administration. “FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer.” April 7, 2021. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-sacituzumab-govitecan-triple-negative-breast-cancer

Was this article helpful? Yes / No
Rn icon

Can we help guide you?

Create a profile for better recommendations



How does this work? Learn more
Are these recommendations helpful? Take a quick survey

Fy22oct sidebarad v02
Back to Top